<DOC>
	<DOCNO>NCT01073865</DOCNO>
	<brief_summary>The purpose study examine efficacy safety well characteristic female hormone study medication administration pre-menopausal woman advance recurrent breast cancer randomise 1:1 ratio either two treatment group ; ZD9393 3.6 mg depot group ZD9393 10.8 mg depot group , give combination tamoxifen tablet .</brief_summary>
	<brief_title>Study Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg Pre-menopausal Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Female ≥20 year premenopausal.Premenopausal define 1 ) last menses within 1 year randomisation , 2 ) E2 ≥10 pg/mL FSH ≤ 30 mIU/mL within 4 week randomisation . For patient hysterectomy , acceptable meet Hormone sensitivity ( ER positive ) primary secondary tumour tissue . Histological/cytological confirmation breast cancer candidate receive hormonal therapy therapy advance breast cancer . Patients receive tamoxifen hormonal therapy adjuvant therapy breast cancer within 24 week randomisation and/or receive prior treatment hormonal therapy advance breast cancer Patients receive LHRHa adjuvant therapy breast cancer within 48 week randomisation Patients relapse adjuvant hormonal therapy within 48 week completion adjuvant hormonal therapy and/or</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ZOLADEX</keyword>
	<keyword>Pre-menopausal</keyword>
	<keyword>Oestrogen Receptor</keyword>
	<keyword>Advanced Breast Cancer</keyword>
	<keyword>Progression Free Survival</keyword>
</DOC>